← Monday, 5 October 2026
72
Impact · ElevatedSEC 8-K · 5 Oct 2026, 11:32 UTC · scored from the filing text

Harrow completes TYRVAYA acquisition from Viatris for $30M

Why it matters

Harrow completed acquisition of TYRVAYA (varenicline nasal spray for dry eye disease) from Viatris on October 1, 2026, paying $30 million in cash plus up to $70 million in contingent milestone payments based on net sales through December 2029. This is a material asset acquisition for an ophthalmic drug with FDA approval, expanding HROW's product portfolio, though the $30M upfront is modest relative to typical M&A and actual revenue impact is contingent on future sales performance.

In plain language

Harrow bought the rights to sell a dry eye disease drug (TYRVAYA) from Viatris for $30 million upfront, with the ability to earn up to $70 million more if it hits sales targets—this gives Harrow a new approved product to commercialize worldwide.

Exposure
Price check
not measured: no fresh price at the time of scoringHow this is measured

Information only. AURA does not give buy or sell recommendations.